Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.55 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.55 |
| ▸ | MAOB | P27338 | 9/20 | 0.52 |
| ▸ | MAOA | P21397 | 7/20 | 0.52 |
| ▸ | KDM1A | O60341 | 6/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.52 |
| ▸ | CYP2B6 | P20813 | 3/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | HTR1A | P08908 | 1/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.52 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | HTR2C | P28335 | 1/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.52 |
| ▸ | DRD3 | P35462 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3966251 | 1.00 | AKR1C3 (0.55) | AKR1C3AKR1C1MAOBMAOAKDM1A | |
| Sulfuric Acid SCHEMBL5870415 | 0.89 | KDM4E (0.61) | AKR1C3AKR1C1MAOBMAOAKDM1A | |
| Sulfuric Acid SCHEMBL5870412 | 0.89 | KDM4E (0.61) | AKR1C3AKR1C1MAOBMAOAKDM1A | |
| Sulfuric Acid SCHEMBL3962603 | 0.89 | KDM4E (0.61) | AKR1C3AKR1C1MAOBMAOAKDM1A | |
| Cadaverine Tartrate SCHEMBL9137056 | 0.85 | AKR1C3 (0.54) | AKR1C3AKR1C1MAOBMAOAKDM1A | |
| SCHEMBL19362020 | 0.82 | AKR1C3 (0.51) | AKR1C3AKR1C1MAOBMAOAKDM1A | |
| SCHEMBL27844124 | 0.82 | AKR1C3 (0.55) | AKR1C3AKR1C1MAOBMAOAKDM1A | |
| SCHEMBL10895189 | 0.81 | AKR1C3 (0.61) | AKR1C3AKR1C1MAOBMAOAKDM1A | |
| SCHEMBL15540828 | 0.80 | AKR1C3 (0.52) | AKR1C3AKR1C1MAOBMAOAKDM1A | |
| SCHEMBL12540252 | 0.80 | AKR1C3 (0.52) | AKR1C3AKR1C1MAOBMAOAKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1517911-B1 | TUMOUR-INHIBITING PLATINUM (II) OXALATE COMPLEXES | KEPPLER PROF DR DR BERNHARD K (AT) | 2009-07-29 | — | — | EP | disclosed |
| US-7057059-B2 | Tumor-inhibiting platinum (II) oxalate complexes | FAUSTUS FORSCHUNGS CIE. TRANSLATIONAL CANCER RESEARCH GMBH (DE) | 2006-06-06 | — | — | US | disclosed |
| US-20050143455-A1 | Tumor-inhibiting platinum (II) oxalate complexes | FAUSTUS FORSCHUNGS CIE. TRANSLATIONAL CANCER RESEARCH GMBH | 2005-06-30 | — | — | US | disclosed |
| EP-1517911-A1 | TUMOUR-INHIBITING PLATINUM (II) OXALATE COMPLEXES | Faustus Forschungs Cie. Translational Cancer Research GmbH (DE) | 2005-03-30 | — | — | EP | disclosed |
| WO-2003106469-A1 | TUMOUR-INHIBITING PLATINUM (II) OXALATE COMPLEXES | FAUSTUS FORSCHUNGS CIE. TRANSLATIONAL CANCER RESEARCH GMBH (DE) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143455-A1 | Tumor-inhibiting platinum (II) oxalate complexes | OXGR1, OAT, OXA1L | AKR1C3 36/4885AKR1C1 190/4885MAOB 1014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.